Compared with control, PD-L1 inhibitors showed significant increase in grade 1-5 pneumonitis and pneumonia (RR, 3.25, 95% CI: 1.61-6.57, p < 0.001, RR, 2.11, 95% CI: 1.20-3.70, p < 0.001). Here, CD274 is linked to susceptibility to pneumonia measurement.